Effect of tissue-specific acetylcholinesterase inhibitor C-547 on α3β4 and αβεδ acetylcholine receptors in COS cells.
The C-547 is the most effective muscle and tissue-specific anticholinesterase among alkylammonium derivatives of 6-methyluracil (ADEMS) acting in nanomolar concentrations on locomotor muscles but not on respiratory muscles, smooth muscles and heart and brain acetylcholine esterases (AChE). When applied systematically it could influence peripheral acetylcholine receptors. The aim of the present study was to investigate the effect of C-547 on rat α3β4 (ganglionic type) and αβεδ (muscle type) nicotinic receptors expressed in COS cells. Currents evoked by rapid application of acetylcholine or nicotine were recorded in whole-cell mode by electrophysiological patch-clamp technique 2-4 days after cell transfection by plasmids coding the α3β4 or αβεδ combination of receptor subunits. In cells sensitive to acetylcholine, the application of C-547 evoked no responses. When acetylcholine was applied during an already running application of C-547, acetylcholine responses were only inhibited at concentrations higher than 10(-7)M. This inhibition is not voltage-dependent, but is accompanied by an increased rate of desensitization. Thus in both types of receptors, effective doses are approximately 100 times higher than those inhibiting AChE in leg muscles and similar to those inhibiting respiratory diaphragm muscles and external intercostal muscles. These observations show that C-547 can be considered for symptomatic treatment of myasthenia gravis and other congenital myasthenic syndromes as an inhibitor of AChE in leg muscles at concentrations much lower than those inhibiting muscle and ganglion types of acetylcholine receptors.
Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
Jiří
J
Lindovský
Konstantin
K
Petrov
Jan
J
Krůšek
Vladimir S
VS
Reznik
Eugeny E
EE
Nikolsky
František
F
Vyskočil
D000109:Acetylcholine / Q000494:pharmacology; D000110:Acetylcholinesterase / Q000378:metabolism*; D000818:Animals; D019556:COS Cells; D002522:Chlorocebus aethiops; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D005724:Ganglia / Q000187:drug effects / Q000378:metabolism; D009132:Muscles / Q000187:drug effects / Q000378:metabolism; D009928:Organ Specificity; D021122:Protein Subunits / Q000378:metabolism*; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology*; D051381:Rats; D011978:Receptors, Nicotinic / Q000378:metabolism*; D014498:Uracil / Q000031:analogs & derivatives* / Q000494:pharmacology
C449662:C-547 compound; D002800:Cholinesterase Inhibitors; D021122:Protein Subunits; D000644:Quaternary Ammonium Compounds; D011978:Receptors, Nicotinic; D014498:Uracil; D000110:Acetylcholinesterase; D000109:Acetylcholine